SARS-CoV-2 seroprevalence survey estimates are affected by anti-nucleocapsid antibody decline

We analyzed 21,676 residual specimens from Ontario, Canada collected between March-August, 2020 to investigate the effect of antibody decline on SARS-CoV-2 seroprevalence estimates. Testing specimens orthogonally using the Abbott (anti-nucleocapsid) and then the Ortho (anti-spike) assays, seropreval...

Descripción completa

Detalles Bibliográficos
Autores principales: Bolotin, Shelly, Tran, Vanessa, Osman, Selma, Brown, Kevin A, Buchan, Sarah A, Joh, Eugene, Deeks, Shelley L, Allen, Vanessa G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7928877/
https://www.ncbi.nlm.nih.gov/pubmed/33400794
http://dx.doi.org/10.1093/infdis/jiaa796
_version_ 1783659901238640640
author Bolotin, Shelly
Tran, Vanessa
Osman, Selma
Brown, Kevin A
Buchan, Sarah A
Joh, Eugene
Deeks, Shelley L
Allen, Vanessa G
author_facet Bolotin, Shelly
Tran, Vanessa
Osman, Selma
Brown, Kevin A
Buchan, Sarah A
Joh, Eugene
Deeks, Shelley L
Allen, Vanessa G
author_sort Bolotin, Shelly
collection PubMed
description We analyzed 21,676 residual specimens from Ontario, Canada collected between March-August, 2020 to investigate the effect of antibody decline on SARS-CoV-2 seroprevalence estimates. Testing specimens orthogonally using the Abbott (anti-nucleocapsid) and then the Ortho (anti-spike) assays, seroprevalence estimates ranged from 0.4%-1.4%, despite ongoing disease activity. The geometric mean concentration (GMC) of antibody-positive specimens decreased over time (p=0.015), and the GMC of antibody-negative specimens increased over time (p=0.0018). The association between the two tests decreased each month (p<0.001), suggesting anti-N antibody decline. Lowering the Abbott antibody index cut-off from 1.4 to 0.7 resulted in a 16% increase in positive specimens.
format Online
Article
Text
id pubmed-7928877
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-79288772021-03-04 SARS-CoV-2 seroprevalence survey estimates are affected by anti-nucleocapsid antibody decline Bolotin, Shelly Tran, Vanessa Osman, Selma Brown, Kevin A Buchan, Sarah A Joh, Eugene Deeks, Shelley L Allen, Vanessa G J Infect Dis Brief Report We analyzed 21,676 residual specimens from Ontario, Canada collected between March-August, 2020 to investigate the effect of antibody decline on SARS-CoV-2 seroprevalence estimates. Testing specimens orthogonally using the Abbott (anti-nucleocapsid) and then the Ortho (anti-spike) assays, seroprevalence estimates ranged from 0.4%-1.4%, despite ongoing disease activity. The geometric mean concentration (GMC) of antibody-positive specimens decreased over time (p=0.015), and the GMC of antibody-negative specimens increased over time (p=0.0018). The association between the two tests decreased each month (p<0.001), suggesting anti-N antibody decline. Lowering the Abbott antibody index cut-off from 1.4 to 0.7 resulted in a 16% increase in positive specimens. Oxford University Press 2021-01-05 /pmc/articles/PMC7928877/ /pubmed/33400794 http://dx.doi.org/10.1093/infdis/jiaa796 Text en © The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Brief Report
Bolotin, Shelly
Tran, Vanessa
Osman, Selma
Brown, Kevin A
Buchan, Sarah A
Joh, Eugene
Deeks, Shelley L
Allen, Vanessa G
SARS-CoV-2 seroprevalence survey estimates are affected by anti-nucleocapsid antibody decline
title SARS-CoV-2 seroprevalence survey estimates are affected by anti-nucleocapsid antibody decline
title_full SARS-CoV-2 seroprevalence survey estimates are affected by anti-nucleocapsid antibody decline
title_fullStr SARS-CoV-2 seroprevalence survey estimates are affected by anti-nucleocapsid antibody decline
title_full_unstemmed SARS-CoV-2 seroprevalence survey estimates are affected by anti-nucleocapsid antibody decline
title_short SARS-CoV-2 seroprevalence survey estimates are affected by anti-nucleocapsid antibody decline
title_sort sars-cov-2 seroprevalence survey estimates are affected by anti-nucleocapsid antibody decline
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7928877/
https://www.ncbi.nlm.nih.gov/pubmed/33400794
http://dx.doi.org/10.1093/infdis/jiaa796
work_keys_str_mv AT bolotinshelly sarscov2seroprevalencesurveyestimatesareaffectedbyantinucleocapsidantibodydecline
AT tranvanessa sarscov2seroprevalencesurveyestimatesareaffectedbyantinucleocapsidantibodydecline
AT osmanselma sarscov2seroprevalencesurveyestimatesareaffectedbyantinucleocapsidantibodydecline
AT brownkevina sarscov2seroprevalencesurveyestimatesareaffectedbyantinucleocapsidantibodydecline
AT buchansaraha sarscov2seroprevalencesurveyestimatesareaffectedbyantinucleocapsidantibodydecline
AT joheugene sarscov2seroprevalencesurveyestimatesareaffectedbyantinucleocapsidantibodydecline
AT deeksshelleyl sarscov2seroprevalencesurveyestimatesareaffectedbyantinucleocapsidantibodydecline
AT allenvanessag sarscov2seroprevalencesurveyestimatesareaffectedbyantinucleocapsidantibodydecline

Ejemplares similares